Home › Uveal Melanoma › Texas
Pag-aaral pangklinika para sa Uveal Melanoma sa Texas
6 pag-aaral para sa Uveal Melanoma ang naghahanap ng mga kalahok sa mga site sa Texas.
Mga Lungsod sa Texas
Opisyal na teksto ng pag-aaral (English)
A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
- The University of Texas MD Anderson Cancer Center, Houston
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 13, 2026 · NCT06805825Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma
- The University of Texas Southwestern Medical Center, Dallas
- UT MD Anderson Cancer Center, Houston
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 12, 2026 · NCT07804186Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions
- The University of Texas MD Anderson Cancer Center, Houston
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Hun 8, 2026 · NCT03947385ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
- University of Texas MD Anderson Cancer Center, Houston
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update May 13, 2026 · NCT03686124Neoadjuvant Darovasertib in Primary Uveal Melanoma
- Austin Retina Associates - Central, Austin
- Texas Retina Associates - Dallas, Dallas
- University of Texas Southwestern Medical Center-5323 Harry Hines Blvd, Dallas
- at 1 pa
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update May 6, 2026 · NCT07015190A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
- UT Southwestern Medical Center, Dallas
- The University Of Texas Md Anderson Cancer Center, Houston
Nagre-recruitPhase 2/3
Lahat ng edad · Lahat ng kasarian · Na-update Abr 2, 2026 · NCT06581406Mula sa ClinicalTrials.gov, na-kuha noong Nob 15, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.